• Home   /  
  • Archive by category "1"

Latest Hepatitis C Research Papers

1. Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717–734.[PubMed]

2. Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol. 2015;21:10790–10810.[PMC free article][PubMed]

3. Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, et al. Chronic hepatitis C: This and the new era of treatment. World J Hepatol. 2016;8:92–106.[PMC free article][PubMed]

4. Madaliński K, Zakrzewska K, Kołakowska A, Godzik P. Epidemiology of HCV infection in Central and Eastern Europe. Przegl Epidemiol. 2015;69:459–464, 581-584.[PubMed]

5. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.[PubMed]

6. World Health Organization. Hepatitis C, WHO fact sheet No. 164, updated July 2015. Available from: http://www.who.int/mediacentre/factsheets/fs164_apr2014/en/

7. Dhingra S, Ward SC, Thung SN. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol. 2016;22:1357–1366.[PMC free article][PubMed]

8. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3–14.[PMC free article][PubMed]

9. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2016;150:145–155.e4; quiz e15-16.[PubMed]

10. Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F, Ramezani-Binabaj M, Miri SM, Alavian SM. Occult HCV Infection: The Current State of Knowledge. Iran Red Crescent Med J. 2015;17:e34181.[PMC free article][PubMed]

11. Rezaee Zavareh MS, Alavian SM. Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies. Hepat Mon. 2015;15:e33462.[PMC free article][PubMed]

12. Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004;85:3173–3188.[PubMed]

13. Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011;19:95–103.[PubMed]

14. Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem. 2002;277:17713–17721.[PubMed]

15. Xu Z, Choi J, Lu W, Ou JH. Hepatitis C virus f protein is a short-lived protein associated with the endoplasmic reticulum. J Virol. 2003;77:1578–1583.[PMC free article][PubMed]

16. Argentini C, Genovese D, Dettori S, Rapicetta M. HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiol. 2009;4:359–373.[PubMed]

17. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007;13:2416–2426.[PMC free article][PubMed]

18. Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5’ noncoding region of hepatitis C virus. Proc Natl Acad Sci USA. 1992;89:4942–4946.[PMC free article][PubMed]

19. Piñeiro D, Martinez-Salas E. RNA structural elements of hepatitis C virus controlling viral RNA translation and the implications for viral pathogenesis. Viruses. 2012;4:2233–2250.[PMC free article][PubMed]

20. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151–178.[PubMed]

21. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–327.[PMC free article][PubMed]

22. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–973.[PubMed]

23. Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis. 2003;16:587–592.[PubMed]

24. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med. 2004;140:370–381.[PubMed]

25. Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH, et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 2012;8:e1002881.[PMC free article][PubMed]

26. Kim T, Mudry RA, Rexrode CA, Pathak VK. Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. J Virol. 1996;70:7594–7602.[PMC free article][PubMed]

27. Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sönnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol. 1996;49:155–160.[PubMed]

28. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol. 2002;76:4034–4043.[PMC free article][PubMed]

29. Morel V, Fournier C, François C, Brochot E, Helle F, Duverlie G, Castelain S. Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat. 2011;18:77–83.[PubMed]

30. Domingo E, Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res. 2007;127:131–150.[PubMed]

31. Biebricher CK, Eigen M. The error threshold. Virus Res. 2005;107:117–127.[PubMed]

32. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol. 2005;79:3071–3083.[PMC free article][PubMed]

33. Echeverría N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015;7:831–845.[PMC free article][PubMed]

34. Pawlotsky JM. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol. 2006;299:261–284.[PubMed]

35. Cody SH, Nainan OV, Garfein RS, Meyers H, Bell BP, Shapiro CN, Meeks EL, Pitt H, Mouzin E, Alter MJ, et al. Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med. 2002;162:345–350.[PubMed]

36. Lin HJ, Seeff LB, Barbosa L, Hollinger FB. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. Hepatology. 2001;34:424–429.[PubMed]

37. Hijikata M, Mizuno K, Rikihisa T, Shimizu YK, Iwamoto A, Nakajima N, Yoshikura H. Selective transmission of hepatitis C virus in vivo and in vitro. Arch Virol. 1995;140:1623–1628.[PubMed]

38. Kojima M, Osuga T, Tsuda F, Tanaka T, Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology. 1994;204:665–672.[PubMed]

39. Cristina J, del Pilar Moreno M, Moratorio G. Hepatitis C virus genetic variability in patients undergoing antiviral therapy. Virus Res. 2007;127:185–194.[PubMed]

40. Valenti L, Pulixi E, La Spina S. IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity? Hepatol Int. 2012;6:356–359.[PubMed]

41. Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. J Virol. 2011;85:5961–5969.[PMC free article][PubMed]

42. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 1997;26:71S–77S.[PubMed]

43. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994;107:812–817.[PubMed]

44. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965.[PubMed]

45. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.[PubMed]

46. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.[PMC free article][PubMed]

47. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.[PMC free article][PubMed]

48. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.[PubMed]

49. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.[PubMed]

50. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther. 2016;43:674–696.[PubMed]

51. Tamori A, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm. 2016;2016:6841628.[PMC free article][PubMed]

52. Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22:861–870.[PubMed]

53. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493–1499.[PubMed]

54. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593.[PubMed]

55. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918–1929.[PMC free article][PubMed]

56. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.[PubMed]

57. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.[PubMed]

58. Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, Davis M, Ruane PJ, Younes Z, Kalmeijer R, et al. Vienna: Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, April 22-26; 2015. A phase 3, randomized, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment- naïve and treatment-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTMIST-1 [abstract] p. Abstract LP14.

59. Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, Godofsky E, Herring R, Poleynard G, Sheikh A, et al. Vienna: Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, April 22-26; 2015. A phase 3, open-lable, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir and sofosbuvironn treatment-naive or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTMIST-2 [abstract] p. Abstract LP04.

60. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.[PubMed]

61. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.[PMC free article][PubMed]

62. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.[PubMed]

63. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, ESchiff E, Ghalib R, Ryan M, et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. N Engl J Med. 2014;370:179–188.[PubMed]

64. Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. J Hepatol. 2016;64:19–28.[PubMed]

65. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.[PubMed]

66. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.[PubMed]

67. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.[PubMed]

68. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373:2608–2617.[PubMed]

69. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–1086.[PubMed]

70. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016;36:189–197.[PubMed]

71. Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Müllhaupt B, Roberts S, et al. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrob Agents Chemother. 2015;59:1282–1291.[PMC free article][PubMed]

72. Sorbera MA, Friedman ML, Cope R. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment. J Pharm Pract. 2016 Epub ahead of print. [PubMed]

73. Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection. Liver Int. 2015;35 Suppl 1:56–64.[PubMed]

74. Craxì L, Sacchini D, Refolo P, Minacori R, Daloiso V, Ricci G, Bruno R, Cammà C, Cicchetti A, Gasbarrini A, et al. Prioritization of high-cost new drugs for HCV: making sustainability ethical. Eur Rev Med Pharmacol Sci. 2016;20:1044–1051.[PubMed]

75. Woode ME, Abu-Zaineh M, Perriëns J, Renaud F, Wiktor S, Moatti JP. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Viral Hepat. 2016;23:522–534.[PubMed]

76. Batista MN, Carneiro BM, Braga AC, Rahal P. Caffeine inhibits hepatitis C virus replication in vitro. Arch Virol. 2015;160:399–407.[PubMed]

77. Finkielsztein LM, Moltrasio GY, Caputto ME, Castro EF, Cavallaro LV, Moglioni AG. What is known about the antiviral agents active against bovine viral diarrhea virus (BVDV)? Curr Med Chem. 2010;17:2933–2955.[PubMed]

78. Bastos JC, Kohn LK, Fantinatti-Garboggini F, Padilla MA, Flores EF, da Silva BP, de Menezes CB, Arns CW. Antiviral activity of Bacillus sp. isolated from the marine sponge Petromica citrina against bovine viral diarrhea virus, a surrogate model of the hepatitis C virus. Viruses. 2013;5:1219–1230.[PMC free article][PubMed]

79. Padilla MA, Rodrigues RA, Bastos JC, Martini MC, Barnabé AC, Kohn LK, Uetanabaro AP, Bomfim GF, Afonso RS, Fantinatti-Garboggini F, et al. Actinobacteria from Termite Mounds Show Antiviral Activity against Bovine Viral Diarrhea Virus, a Surrogate Model for Hepatitis C Virus. Evid Based Complement Alternat Med. 2015;2015:745754.[PMC free article][PubMed]

80. Jardim AC, Igloi Z, Shimizu JF, Santos VA, Felippe LG, Mazzeu BF, Amako Y, Furlan M, Harris M, Rahal P. Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res. 2015;115:39–47.[PMC free article][PubMed]

81. Calland N, Dubuisson J, Rouillé Y, Séron K. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses. 2012;4:2197–2217.[PMC free article][PubMed]

82. Li Y, Yu S, Liu D, Proksch P, Lin W. Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L. Bioorg Med Chem Lett. 2012;22:1099–1102.[PubMed]

83. Kubiça TF, Alves SH, Weiblen R, Lovato LT. In vitro inhibition of the bovine viral diarrhoea virus by the essential oil of Ocimum basilicum (basil) and monoterpenes. Braz J Microbiol. 2014;45:209–214.[PMC free article][PubMed]

84. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010;51:1912–1921.[PMC free article][PubMed]

85. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One. 2011;6:e16464.[PMC free article][PubMed]

86. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. Inhibition of HCV 3a core gene through Silymarin and its fractions. Virol J. 2011;8:153.[PMC free article]

1. Massroor AM, Zahoor SZ, Akbar SM, Shaukat S, Butt AJ, Naeem A, Sharif s, Angez M. Molecular epidemiology of Hepatitis B virus genotypes in Pakistan. BMC Infectious Diseases. 2007;7:115. doi: 10.1186/1471-2334-7-115.[PMC free article][PubMed][Cross Ref]

2. Chen Stephen L, Morgan Timothy R. The Natural History of Hepatitis C Virus (HCV) Infection. International Journal of Medical Sciences. 2006;3(2):47–52.[PMC free article][PubMed]

3. CDC 2006, author. Uganda HIV/AID sero- behavioural survey. 2004–2005.

4. Tamale-Basudde TB, Mugyenyi PN. Prevalence of hepatitis c virus in patients infected with human immune deficiency virus at joint clinical research centre in Uganda. Int Conf AIDS. 2002;14(C10968):7–12. 2002.

5. Hladik W, Kataaha P, Mermin J, Purdy M, Otekat G, Lackritz E, Alter J M, Downing R. Prevalence and screening costs of HCV virus among Ugandan blood donors. Trop Med Int Health. 2006;11(6):951–954.[PubMed]

6. Yun-Fan L, Tung H. Chronic hepatitis B virus infection acquired in childhood, Taiwan. Journal of viral hepatitis. 2006;14(3):147–152.

7. Alter Miriam J. Epidemiology of viral Hepatitis and HIV Co-infection. Journal of Hepatology. 2006;44(1):S6–S9.[PubMed]

8. Soriano V, Barreiro P, Nuñez M. Management of chronic hepatitis B and C in HIV coinfected patients. Journal of antimicrobial therapy. 2006;57(5):815–818.[PubMed]

9. Benhamou Yves. Antiretroviral therapy and HIV/Hepatitis B virus co infection. Journal of clinical infectious diseases. 2004;38(2):S98–S103.[PubMed]

10. Sulkowski M S. Therapeutic issues in HIV/HCV co-infected patients. 600 North Wolfe Street, 1830 Building, Room 448, Baltimore, MD 21287-0003, USA: Viral Hepatitis center, Johns Hopkins University School of Medicine; 2007.

11. Bwogi Josephine, Braka Fiona, Makumbi Issa, Mishra Vinod, Bakamutumaho Barnabas, Nanyunja Miriam, Opio Alex, Downing Robert, Biryahwaho Benon, Lewis Rosamund F. Hepatitis B Infection is Highly endemic in Uganda: Findings From a National Serosurvey. African Health Sciences. 2009;9(2)[PMC free article][PubMed]

12. Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, Thakkinstian A. Prevalence of Hepatitis B Virus and Hepatitis C Virus Co-infection with Human Immunodeficiency Virus in Thai Patients, Int Conf AIDS. Journal of Medical association, Thailand. 2004;87(11):1349–1354.[PubMed]

13. Rizzardini G, Ferrante P, Fabiani M, Lukwiya M, Mancuso R, Declich S, Clerici M. HCV/HIV prevalence in women attending the Ante Natal Clinic of Lacor Hospital in northern Uganda. Int Conf AIDS. 2000;13(C2407):9–14.

14. Highleyman L. Women and HCV, chronic Hepatitis C Is Mild in menstruating women. Journal of Gastroenterology and Hepatology. 2005;15(12):1411–1417.[PubMed]

15. Tankhiwale SS, Khadase RK, Jalgoankar SV. Seroprevalence of anti- HCV and hepatitis B surface antigen in HIV infected patients. Indian Journal of Medical Microbiology. 2003;21(4):268–270.[PubMed]

16. Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A, Colebunders R, Thomas DL. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010[PMC free article][PubMed]

One thought on “Latest Hepatitis C Research Papers

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *